Please find enclosed.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the USFDA for its Injectable Facility (F-III) located at Karakhadi. The USFDA conducted the inspection from February 9-18, 2026, and the EIR was issued on May 13, 2026. Receiving an EIR indicates the inspection has concluded with no critical observations, representing a positive regulatory outcome for the company's injectable manufacturing capabilities.
The EIR clearance removes regulatory uncertainty around the Karakhadi injectable facility and supports Alembic's ability to serve the US market with sterile injectable products, potentially boosting future revenue from regulated markets.